NCCN

Kexing Biopharm Teams Up with Qingfeng Pharma for the Global Market on Olaparib Tablets

Retrieved on: 
Freitag, Mai 10, 2024
USD, Cancer, NCCN, Trastuzumab, Tablet, GC, PARP, Pancreatic cancer, Breast cancer, Prostate cancer, BRCA, Eribulin, Malignancy, Marketing, GMP, Paclitaxel, EPO, Ovarian cancer, Birth control

Kexing Biopharm signed a cooperation agreement with Kerui Pharma, a subsidiary of Qingfeng Pharmaceutical Group (hereinafter referred to as "Qingfeng Pharma"), for the international commercialization of Olaparib Tablets.

Key Points: 
  • Kexing Biopharm signed a cooperation agreement with Kerui Pharma, a subsidiary of Qingfeng Pharmaceutical Group (hereinafter referred to as "Qingfeng Pharma"), for the international commercialization of Olaparib Tablets.
  • The agreement grants Kexing Biopharm the rights to commercialize Qingfeng Pharma-manufactured Olaparib Tablets in 10 oversea countries.
  • Since the beginning of 2024, Kexing Biopharm has received numerous on-site GMP inspections by health authorities from various oversea countries.
  • As the company licenses in more new products, its global presence will continue to grow, and mark a bright future.

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Donnerstag, Mai 9, 2024
CVR, CHRS, FDA, GAAP, TSA, Total, NCCN, Investment, Ophthalmology, Conference call, Research, CRI, Conference, ADCC, Exercise, Cancer Research Institute, Medicare Advantage, Acquisition, NPC, Medicare, COGS, Ovarian cancer, Relative value unit, Pharmaceutical industry

REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended March 31, 2024 and recent business highlights: 

Key Points: 
  • Total unit demand grew 36% in Q1 2024 compared to Q4 2023 and represented a 108% increase compared to Q1 2023.
  • Based on data from IQVIA, UDENYCA franchise market share for Q1 2024 was 25%, an increase of 10 market share points in Q1 2024 compared to Q4 2023.
  • LOQTORZI, the first and only FDA-approved treatment for recurrent, locally advanced or metastatic NPC, commercially launched on January 2, 2024.
  • Coherus projects combined R&D and SG&A expenses for 2024 to be in the range of $250 to $265 million.

Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone

Retrieved on: 
Dienstag, Mai 7, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Cancer, NCCN, Lung cancer, Publication, Colorectal cancer, National Comprehensive Cancer Network, Companion diagnostic, National Cancer Institute, Helmy Eltoukhy, NCI, CDX, Trust, Breast cancer, Liquid biopsy

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its achievement of surpassing a significant milestone of 500 peer-reviewed publications featuring its technology in esteemed scientific journals.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its achievement of surpassing a significant milestone of 500 peer-reviewed publications featuring its technology in esteemed scientific journals.
  • This milestone highlights Guardant Health’s leadership, amassing one of the most robust portfolios of relevant liquid biopsy research studies in the industry.
  • “We have partnered with thousands of authors representing diverse perspectives and expertise worldwide,” said Dr. Craig Eagle, chief medical officer at Guardant Health.
  • “High-quality science has always been the driving force in our mission to conquer cancer with data,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO.

Veracyte Announces First Quarter 2024 Financial Results

Retrieved on: 
Dienstag, Mai 7, 2024
Technology, Health Technology, Software, Biometrics, Biotechnology, Pharmaceutical, Health, Data Management, Oncology, Artificial Intelligence, Table, GAAP, Prostate, NCCN, Investment, MRD, Abstract, National Comprehensive Cancer Network, Webcast, JCO, Growth, Prostate cancer, Patient, Acquisition, Medicare, Metabolism, Genomics, Annual general meeting, Waiting, Endocrinology, Bladder cancer, Journal

Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2024.
  • Total revenue for the first quarter of 2024 was $96.8 million, an increase of 17% compared to $82.4 million reported in the first quarter of 2023.
  • Net loss for the first quarter of 2024 was $1.9 million, an improvement of 77% compared to the first quarter of 2023.
  • Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update.

14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

Retrieved on: 
Montag, Mai 6, 2024
Oncology, Health, Technology, Health Technology, Genetics, Artificial Intelligence, Biotechnology, RUO, University, Prostate, NCCN, RC, International, RP, Risk, Grade, American Urological Association, Survival, Neoadjuvant therapy, PSA, Columbia University, Integration, Research, Pathology, GSC, Prostate cancer, Prostate-specific antigen, University of Michigan, Patient, NOC, Urology, Intelligence, AUA, MRI, Biopsy, Gene expression, Diagnosis, MUSIC, Waiting, Bladder cancer, Radical, Medical imaging

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers provide better prognostic information for patients with prostate and bladder cancer, compared to standard approaches.

Key Points: 
  • (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers provide better prognostic information for patients with prostate and bladder cancer, compared to standard approaches.
  • They also show that the research-use-only Decipher GRID (Genomic Resource for Intelligent Discovery) tool is helping to advance scientific understanding of these diseases.
  • Summary: The Decipher Prostate Genomic Classifier is associated with adverse pathology in patients eligible for Active Surveillance (AS) who were treated with radical prostatectomy (RP).
  • Podium Presentation PD42-03 : Understanding Population-Wide Genomic Risk Distribution and Integrating Clinical-Genomic Risk for Prognostication in Prostate Cancer.

NCCN Policy Summit Encourages Conversation and Action on Sexual Health and Fertility Issues Faced by People with Cancer

Retrieved on: 
Montag, Mai 6, 2024
Education, Adolescence, Fertility, City, Research, National LGBT Cancer Network, Doctor of Philosophy, Gynecologic Oncology (journal), Life, ASCO, Cancer, Concurrent estate, Cervical cancer, Virtual, Cancer prevention, NCCN, Fertility preservation, Infertility, National Comprehensive Cancer Network, Oncology, Survivor, JD, Reproductive Sciences, Quality of life, Patient, OBGYN, Gynaecology, Family, MPH, Division, Fox Chase Cancer Center, Human, Assistant professor, Policy, Associate professor, Obstetrics, UCSF, MBA, Birth control

WASHINGTON, May 6, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—hosted an oncology policy summit, today, focused on how sexual and reproductive health can impact people with cancer before, during, and after treatment. Speakers covered a wide range of topics, within the context of gender and sex, intimacy, fertility and reproductive health, treatment side-effects, and the impact of a changing policy landscape in the wake of new laws and judicial decisions.

Key Points: 
  • WASHINGTON, May 6, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—hosted an oncology policy summit, today, focused on how sexual and reproductive health can impact people with cancer before, during, and after treatment.
  • These evidence-based expert consensus recommendations feature best practices for addressing sexual health, fertility, hormone-related symptoms, and many other late and long-term effects from cancer.
  • "It is so important that education about sexual and reproductive health be included into the training of cancer clinicians if these critical health issues are to be addressed in patients' comprehensive cancer care."
  • Two afternoon keynote speakers shared first-hand looks at the issue of reproductive health and fertility preservation for people undergoing cancer care.

DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck

Retrieved on: 
Freitag, Mai 3, 2024
Surgery, Genetics, Clinical Trials, Biotechnology, Biometrics, Health, Pharmaceutical, General Health, Oncology, Radiation, Mohs, NCCN, Mohs surgery, American College, CME, ACMS, Abstract (summary), Neck, National Comprehensive Cancer Network, SCC, Patient, Metastasis, Neoplasm, Head, BWH

“In most cases, once a tumor is removed completely, the patient is in the clear.

Key Points: 
  • “In most cases, once a tumor is removed completely, the patient is in the clear.
  • This study included 417 patients who received definitive Mohs surgery to remove high-risk SCC tumors of the H&N with reported clear margins.
  • Presenting authors will be available to answer questions regarding their posters on Saturday, May 4, from 12-1 p.m. Mountain Standard Time.
  • Abstracts will also be in ACMS' CME & Abstract Book and available for online viewing via the Planstone abstract site.

Castle Biosciences Reports First Quarter 2024 Results

Retrieved on: 
Donnerstag, Mai 2, 2024
Oncology, Mental Health, Health, Biometrics, General Health, Pharmaceutical, Biotechnology, Epidemiology, NCCN, News, Hospital, Risk, Recurrence, Lymph node, ART, Patient, Metastasis, Medicare, Trial of the century, Melanoma, Pharmaceutical industry

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2024.
  • Delivered 20,888 total test reports in the first quarter of 2024, an increase of 40% compared to 14,916 in the same period of 2023:
    DecisionDx-Melanoma test reports delivered in the quarter were 8,384 compared to 7,583 in the first quarter of 2023, an increase of 11%.
  • MyPath® Melanoma test reports delivered in the quarter were 998, compared to 980 MyPath Melanoma and DiffDx®-Melanoma aggregate test reports in the first quarter of 2023, an increase of 2%.
  • Castle Biosciences will hold a conference call on Thursday, May 2, 2024, at 4:30 p.m. Eastern time to discuss its first quarter 2024 results and provide a corporate update.

Thyme Care Recruits Palliative Care Physician from Mount Sinai to Launch Enhanced Supportive Care Services

Retrieved on: 
Donnerstag, Mai 2, 2024
Pain, Cancer, NCCN, Palliative care, Princeton University, National Comprehensive Cancer Network, MD, Research, Workflow, Oncology, Mount Sinai Health System, Senior, Patient, Caregiver, Harvard Medical School, Hospice, Quality of life, Overalls, Nursing

NASHVILLE, Tenn., May 2, 2024 /PRNewswire/ -- Thyme Care, the leading value-based cancer care enabler, today announced Julia Frydman, MD as the company's first medical director for palliative care. An academic researcher and former assistant professor from a leading health system renowned for its palliative care and geriatrics department, Dr. Frydman brings important clinical expertise to Thyme Care and will launch the company's Enhanced Supportive Care services. This virtual palliative care program will help eligible members and their caregivers manage physical and psychological symptoms and provide an additional layer of support as they navigate living with cancer.

Key Points: 
  • An academic researcher and former assistant professor from a leading health system renowned for its palliative care and geriatrics department, Dr. Frydman brings important clinical expertise to Thyme Care and will launch the company's Enhanced Supportive Care services.
  • From the perspective of community oncologists, the most important barriers are perceived resistance from patients and caregivers regarding palliative care discussions, and many practices lack dedicated palliative care staff .
  • As the new medical director for palliative care, Dr. Frydman will launch Thyme Care's Enhanced Support Care Services.
  • I see Thyme Care as being in a unique position to support oncologists in delivering exceptional care to their communities and improving access to palliative care where services are not currently available.

Resource-Appropriate Cancer Care, Including Coexisting Health Issues of HIV and Cancer, to be Addressed During Meeting in Nairobi

Retrieved on: 
Mittwoch, Mai 1, 2024
Cancer, NCCN, AIDS, ACC, Safety, American Cancer Society, Uganda Cancer Institute, HIV/AIDS, ACS, CHAI, Senior, Clinton Foundation, Patient, MPH, Drug, HIV, MBA, Kaposi's sarcoma, Non-Hodgkin lymphoma, Dietary supplement

NAIROBI, Kenya, May 1, 2024 /PRNewswire/ -- Local and global experts are meeting in Nairobi, Kenya to update clinical practice guidelines as part of ongoing work with Allied Against Cancer—a collaboration between the National Comprehensive Cancer Network® (NCCN®), African Cancer Coalition (ACC), American Cancer Society (ACS), and Clinton Health Access Initiative (CHAI). The meeting brings together subject matter experts to update NCCN Harmonized Guidelines™ for Sub-Saharan Africa, featuring updates for treating cancer in people with HIV and other important topics. The event runs from May 1-3, 2024.

Key Points: 
  • The meeting brings together subject matter experts to update NCCN Harmonized Guidelines™ for Sub-Saharan Africa, featuring updates for treating cancer in people with HIV and other important topics.
  • "Many cancers occur more frequently in people with HIV and AIDS, including AIDS-defining cancers like non-Hodgkin lymphoma, Kaposi sarcoma, and invasive cervical cancer.
  • The NCCN Harmonized Guidelines™ employ color-coded recommendations to delineate the best possible cancer care across various settings and resource availability.
  • The Nairobi meeting will focus on updates to the NCCN Harmonized Guidelines™ for People Living with HIV, as well as the following cancer types: